About US
Contact us
-
Pfizer pulls mixed-up contraceptive pillsPill mix-ups and potency questions have prompted dozens of recalls in recent months. This time, the potential for both has Pfizer ($PFE)pulling 1 million packages of contraceptive pills. The balance2012/2/2
-
WSJ: Another executive shake-up at J&J's McNeil unitJohnson & Johnson ($JNJ) is taking an eraser to its McNeil Consumer Healthcare org chart again. Less than 12 months after a management shake-up put them in positions crucial to a McNeil turnarou2012/2/1
-
Pfizer, Lilly earnings drop on new generic rivalsPfizer ($PFE) and Eli Lilly ($LLY) are continuing the downward-sloping earnings trend that's dominated Big Pharma's fourth-quarter reports. Pfizer saw profits drop by half, while Lilly's earning2012/2/1
-
Spain's drug spending drops as pharma debt mountsSpain is trying to fix its prescription-drugs spending, but so far, it's only managed to cause drugmakers pain. As PharmaTimes reports, the austerity-minded country cut its drug spending8.8% last ye2012/2/1
-
Roche, Pfizer win FDA nods for targeted cancer drugsRoche ($RHHBY) and Genentech won a landmark approval for the cancer drug vismodegib today. After gaining significant efficacy data from a Phase II study on basal cell carcinoma, the drug giant not onl2012/1/31
-
Lipitor brand loses ground as generics take holdPfizer ($PFE) faces another stumbling block on its Lipitor obstacle course. As The Wall Street Journal reports, Express Scripts ($ESRX) is moving the cholesterol drug to a less-favorable spot on i2012/1/31
-
FDA weighs crackdown on 'distracting images' in DTC adsIn every pharmaceutical television commercial there's the bit at the end while a voiceover intones a litany of potential side effects anddrug warnings likely to startle anyone thinking of taking it.2012/1/31
-
Ax hovers over 3,000 more AstraZeneca jobs, U.K. papers sayThe 2012 layoffs toll may continue to mount. British newspapers are reporting that AstraZeneca's ($AZN) cost-squeezing program could grow by another 3,000 or so job cuts. The company is said to be2012/1/30
-
Jimenez counts on 7 drugs to take Novartis past DiovanMaybe it's the rarefied Davos air or the long-range mountain views, but Novartis ($NVS) CEO Joe Jimenez is feeling optimistic about the post-Diovan future. After the Swiss drugmaker loses patent pro2012/1/30
-
Sanofi, Novartis favor diagnostics partnerships over M&AThe initial speculation--or was it a wish?--that a Sanofi ($SNY) or Novartis ($NVS)might mount a counterbid to Roche's hostile $5.7 billion offer for Illumina was chilled rather effectively by a sto2012/1/30